Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Study Of Patients With Allergic Rhinitis And Asthma

ClinicalTrials.gov ID: NCT00296530

Public ClinicalTrials.gov record NCT00296530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.

Study identification

NCT ID
NCT00296530
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
600 participants

Conditions and interventions

Eligibility (public fields only)

Age range
15 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2005
Primary completion
Jun 30, 2007
Completion
Jun 30, 2007
Last update posted
Oct 27, 2016

2005 – 2007

United States locations

U.S. sites
80
U.S. states
29
U.S. cities
70
Facility City State ZIP Site status
GSK Investigational Site Ozark Alabama 36360
GSK Investigational Site Tempe Arizona 85282
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Long Beach California 90808
GSK Investigational Site Los Angeles California 90095-1752
GSK Investigational Site Orange California 92868
GSK Investigational Site Palmdale California 93551
GSK Investigational Site Riverside California 92506
GSK Investigational Site San Diego California 92123
GSK Investigational Site San Jose California 95128
GSK Investigational Site Stockton California 95207
GSK Investigational Site Vista California 92083
GSK Investigational Site Colorado Springs Colorado 80907
GSK Investigational Site Denver Colorado 80206
GSK Investigational Site Denver Colorado 80230
GSK Investigational Site Wheat Ridge Colorado 80033
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Miami Florida 33176
GSK Investigational Site Sarasota Florida 34239
GSK Investigational Site Tampa Florida 33613
GSK Investigational Site Lawrenceville Georgia 30045
GSK Investigational Site Lilburn Georgia 30047
GSK Investigational Site Marietta Georgia 30060
GSK Investigational Site Kenilworth Illinois 60043
GSK Investigational Site Iowa City Iowa 52242
GSK Investigational Site Covington Louisiana 70433
GSK Investigational Site Lafayette Louisiana 70503
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Baltimore Maryland 21236
GSK Investigational Site Bethesda Maryland 20814
GSK Investigational Site Chevy Chase Maryland 20815
GSK Investigational Site North Andover Massachusetts 01845
GSK Investigational Site Ypsilanti Michigan 48197
GSK Investigational Site Rolla Missouri 65401
GSK Investigational Site Omaha Nebraska 68130
GSK Investigational Site Ocean City New Jersey 07712
GSK Investigational Site Skillman New Jersey 08558
GSK Investigational Site Ithaca New York 14850
GSK Investigational Site Charlotte North Carolina 28204
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cincinnati Ohio 45231
GSK Investigational Site North Olmsted Ohio 44070
GSK Investigational Site Sylvania Ohio 43560
GSK Investigational Site Oklahoma City Oklahoma 73104
GSK Investigational Site Oklahoma City Oklahoma 73120
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Lake Oswego Oregon 97035
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Collegeville Pennsylvania 19426
GSK Investigational Site Gibsonia Pennsylvania 15044
GSK Investigational Site Philadelphia Pennsylvania 19115
GSK Investigational Site Philadelphia Pennsylvania 19140
GSK Investigational Site East Providence Rhode Island 02914
GSK Investigational Site Providence Rhode Island 02906
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Charleston South Carolina 29414
GSK Investigational Site Greer South Carolina 29651
GSK Investigational Site Chattanooga Tennessee 37421
GSK Investigational Site Germantown Tennessee 38138
GSK Investigational Site Austin Texas 78704
GSK Investigational Site Austin Texas 78750
GSK Investigational Site Corsicana Texas 75110
GSK Investigational Site Dallas Texas 75230
GSK Investigational Site Dallas Texas 75231-4307
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site El Paso Texas 79902
GSK Investigational Site El Paso Texas 79925
GSK Investigational Site Houston Texas 77054
GSK Investigational Site Houston Texas 77070
GSK Investigational Site Killeen Texas 76542
GSK Investigational Site Plano Texas 75093
GSK Investigational Site San Antonio Texas 78205
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Waco Texas 76712
GSK Investigational Site Murray Utah 84107
GSK Investigational Site West Jordan Utah 84084
GSK Investigational Site South Burlington Vermont 05403
GSK Investigational Site Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00296530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 27, 2016 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00296530 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →